Tech Company Financing Transactions

Neurophth Therapeutics Funding Round

Neurophth Therapeutics secured a $60 million Series C venture capital round on 11/24/2021. Backers included SDIC Fund Management, Sequoia Capital and China Merchants Venture Capital.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

3rd Floor Building B1 Optics Valley Biological City No.666 G C270-C271
Wuhan Hubei Province, Undisclosed
China

Phone

+86-27-65524119

Website

www.neurophth.com

Email Address

[email protected]

Overview

Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Li Bin

        

Chief Executive Officer

Alvin Luk

        

Chief Financial Officer

Su Zhang

        

Chief Operating Officer

Xin Zhang

        

Chief Scientific Officer

Qiutang Li

        

Chief Technical Officer

Bose Kalampanayil

        

Co-Founder

Dabo Cai

        

General Manager

Su Xiao

        

Vice President

Luke Li

        

VP - Human Resources

Jane Yang

        

VP - Regulatory Affairs

Cao Yang

        

Browse more venture capital transactions:

Prev: 11/24/2021: Fractional venture capital transaction
Next: 11/24/2021: WatchBox venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary